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Abstract
Background: Study of a clinic case reveals that alpha-1-antitrypsin (AAT) deficiency is related to CD4+ T cell count
decline and AIDS progression, suggesting that AAT might be an endogenous inhibitor of HIV/AIDS. Previous study
shows that AAT inhibits HIV-1 replication in infected host cells and the C-terminus fragment of AAT, VIRIP, interferes
with HIV-1 infection. However, it is still unclear whether and how intact AAT inhibits HIV-1 infection. It is also unknown
what the mechanism of AAT is and which critical step(s) are involved.
Results: In the present study, the C-terminus of AAT (C) was synthesized. C terminus-truncated AAT (ΔAAT) was
also prepared by digesting AAT with metalloproteinase. Primary CD4+ T cells were then co-cultured with HIV-1
with the presence or absence of AAT/C/ΔAAT to detect cis-infection of HIV-1. The interaction between
AAT/C/ΔAAT and gp120/gp41 was also measured. Meanwhile, HIV-1 reverse transcriptase activity and viral DNA
integration were also detected in these lymphocytes. The results demonstrated that AAT and C, not ΔAAT,
inhibited HIV-1 entry by directly interacting with gp41. Meanwhile, AAT, C and ΔAAT could not directly interfere
with the steps of viral RNA reverse transcription and viral DNA integration.
Conclusion: AAT inhibits HIV-1 entry by directly interacting with gp41 through its C-terminus and thereby
inhibits HIV-1 infection.
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Background
Human immunodeficiency virus type 1 (HIV-1) is hard
to propagate in infected and unaltered whole blood,
unless the blood is diluted and active lymphocytes are
present [1, 2]. Investigations of HIV-1 replication in
patients reveal that HIV-1 proliferation is confined in
the lymph nodes where the concentration of specific
serum constituents is lower [3, 4]. These facts suggest
that human body produces endogenous inhibitors for
HIV and acquired immune deficiency syndrome
(AIDS) progression. Further studies show that various
components in human blood and tissues are possible
candidates [5–7]. Among these components, serine
protease inhibitors are promising. Studies report that
salivary secretary leukocyte protease inhibitor suppresses
HIV-1 replication [8, 9]. Researchers also focus on
alpha-1-antitrypsin (AAT), a 394 amino acid, 52 kDa
glycoprotein synthesized in the liver and secreted into
the circulation [10–15]. AAT is consistently present
in the serum of healthy individuals (1.5 ~ 3.5 mg/mL),
although its concentration can increase several times
upon inflammation [16, 17]. Study of a clinic case re-
veals that pre-existing AAT deficiency is associated
with accelerated HIV/AIDS progression, which sug-
gests that AAT might be an endogenous HIV/AIDS
suppressor [13, 18].
The lifespan of HIV can be divided into two major
processes, infection and replication [19, 20]. HIV-1 in-
fection begins with the interaction between viral gp120/
gp41 and CD4/co-receptors on host cells and ends with
the integration of viral DNA into host genome. This
process contains several middle steps, including the
entry of viral core, reverse transcription of viral RNA
and nuclear translocation of viral DNA [21, 22]. HIV-1
replication begins with the transcription and translation
of viral genes, which lead to the package, budding and
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release of new virus, which is then processed to become
infection-competent virus [23]. Our previous study re-
veals that AAT enters the cytosol of infected CD4+ T
cells through LRP1-mediated endocytosis process, where
it directly interacts with nuclear factor kB (NF-kB) in-
hibitor (IkBα) and thereby alters its ubiquitinylation pat-
tern to block NF-kB activation and HIV-1 replication
[14, 24, 25]. Munch’s study suggests that the C-proximal
fragment of AAT (A.A. 353–372), VIRIP, inhibits HIV-1
infection [12]. However, it is unclear whether and how
intact 55KD AAT interacts with gp120-covered gp41on
the viral membrane to inhibit HIV-1 infection, due to its
big size that might shield its VIRIP domain. It is also un-
known whether AAT inhibits HIV-1 infection by target-
ing on single or multiple steps: viral core entry, viral
RNA reverse transcription or viral DNA integration.
Moreover, it is still unclear whether C-terminus of AAT
is the only functional domain.
In the present study, we sought to investigate the ac-
curate mechanism of intact AAT inhibiting HIV infec-
tion. The results demonstrate that AAT and synthesized
C-terminus fragment of AAT (C), not C-terminus-
truncated AAT (ΔAAT), inhibits HIV-1 entry into CD4+
T cells. The inhibitory effect is mediated through their
direct interactions with gp41. Additionally, AAT, C and
ΔAAT did not directly affect the steps of viral RNA re-
verse transcription and viral DNA integration. Thus,
our results clarify how AAT inhibits HIV-1 infection
in primary CD4+ T cells. Combined with the previous
finding that AAT inhibits HIV-1 replication in in-
fected cells [15, 24, 25], it is clear that AAT can sup-
press HIV/AIDS pathogenesis through inhibiting both
HIV infection and replication in vitro, which might




Human plasma AAT was obtained from Sigma [purity
and quality were analyzed by electrophoresis and mass
spectrometry following the methods described below
(Additional file 1: Figure S1)]. ΔAAT were prepared by
digesting AAT. Briefly, AAT and metalloproteinase from
S. aureus (Sigma) were co-cultured at 40:1 (molar ratio)
for 3 h at 37 °C in 50 mM NH4HCO3. Next, protease
was removed by using HiTrap benzamidine column
(Amersham) and then passed through 10KD MWCO
spin filter (Millipore) to separate truncated AAT. The
truncation of AAT was verified by electrophoresis and
mass spectrometry (Additional file 1: Figure S1) and also
justified by the loss of ability to bind trypsin and elastase
(Sigma) [26, 27]. C-terminus of AAT (C) (A.A. 345–384:
KGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIDQNT
KSP) was synthesized in Genscript and the purity and
accuracy of peptide was also analyzed by electrophor-
esis and mass spectrometry (Additional file 1: Figure S1).
HIV-1 integrase inhibitor raltegravir (RAL), HIV-1 reverse
transcriptase inhibitor emtricitabine (FTC) and HIV-1
entry inhibitor enfuvirtide (ENF) were from Santa Cruz
Biotechnology.
HIV-1 preparation
HIV-1 stock was prepared by propagating HIV-1NL4.3
(X4 virus) in mitogen-stimulated peripheral blood
mononuclear cells (PBMC) as before [24]. Unless other-
wise noted, HIV-1 infection was performed using HIV-
1NL4.3. HIV-1 primary isolates, 91US054 (X4 virus) or
92US714 (R5 virus) (NIH AIDS Research and Reference
Reagent Program), were also propagated in mitogen-
stimulated PBMCs in complete culture medium (CM)
[RPMI1640 with HEPES (20 mM), nonessential amino
acids, L-glutamine (2 mM), 10 % heat-inactivated, de-
fined FBS (Life Technologies/Invitrogen) and gentamicin
(50 mg/ml; Life Technologies)]. Additionally, GFP-
labeled HIV-1NL4.3 was made by transfecting a vector
coding for HIV-1NL4.3 with GFP insertion in gag region
(HIV-1 Gag-iGFP) into HEK293T cells. GFP-labeled
pseudotyped HIV-1NL4.3 was made by transfecting a vec-
tor coding for HIV-1NL4.3 with GFP insertion in gag re-
gion and VSV-G replacing of Env (VSV-G-pseudotyped
HIV-1 Gag-iGFP) into HEK293T cells (both vectors were
generous gifts from Dr. Yuntao Wu; Dr. Wu also pro-
vided us pure gp120 and gp41). After harvesting, virus
was purified, concentrated, and stored in −80 °C.
CD4+ T cell isolation and infection
PBMCs were extracted from the whole blood of
healthy, HIV-negative donors using Ficoll-Paque-Plus
(GE Healthcare) as directed. CD4+ T cells were then
isolated from these PBMCs using a CD4+ T cell isola-
tion Kit II (Miltenyi Biotech) as directed. Next, iso-
lated CD4+ T cells were activated and maintained as
before [15]. To ensure that CD4- and coreceptor-
dependent infection (cis-infection) is not interfered by
the endocytosis of viral particle that is an alternative
way of HIV infection in some cases (trans-infection)
[28], activated CD4+ T cells were cultured for 30 min
in conditioned complete medium [complete medium
with the endocytosis inhibitor cocktail (5 μg/mL
methyl-beta-cyclodextrin, filipin and chlorpromazine)]
before and during infection, which was washed off
after 2 h’ infection and maintained in normal complete
medium when prolonged incubation was needed.
ELISA assay for HIV-1 p24 detection
To detect cytosol p24, CD4+ T cells were cultured with
HIV-1. These cells were then suspended in Lysis Buffer
[50 mM Tris–HCl (pH7.4), 1 % CHAPS, 250 mM NaCl,
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0.5 % Triton X-100, 1 % Igepal CA-630, 1 mM DTT,
1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, 4 mM EDTA,
protease inhibitor cocktail (Roche)] and vortexing for
60 s. The mixture was then incubated on ice for 15 min
and homogenized with a small gauge needle by drawing
3 times. After homogenizing, the mixture was centri-
fuged at 14,000 × g for 10 min at 4 °C to collect the
supernatant (whole cell proteins containing viral pro-
teins). HIV-1 p24 was detected using the HIV-1 p24
antigen ELISA kit (ZeptoMetrix Corporation) following
the direction. For HIV-1 replication, the supernatant
fluid of the culture system was collected to detect HIV-1
p24 using the HIV-1 p24 antigen ELISA kit (ZeptoMetrix
Corporation) following the direction.
HIV-1 RNA detection
Supernatant with HIV-1 viral particles was collected
for viral RNA quantitation. Viral RNA was isolated
using QIAamp viral RNA mini Kit (Qiagen). Isolated
viral RNA was reverse-transcribed into cDNA using
random primers and Superscript III reverse transcript-
ase (Invitrogen). Quantitative RT-PCR using TaqMan
Universal PCR Master Mix (Applied Biosystems) used
the following primers and probe: forward primer: 59-
TGGGTACCAGCACACAAAGG-39 (nt 3696 in
HXB2); reverse primer: 59-ATCACTAGCCATTGC
TCTCCAAT-39 (nt 3850 in HXB2); and probe:
ATTGGAGGAAATGAAC-MBG (FAM labeled) at 900
nM (primers) and 250 nM (probe). Quantitative PCR
conditions were as follows: 50 °C for 2 min (1 cycle),
95 °C for 10 min (1 cycle), followed by 60 cycles of:
95 °C for 15 s and 60 °C for 1 min in an ABI 7500
thermocycler (Applied Biosystems). A standard curve
was prepared using known concentrations (i.e., copy
numbers) of ACH-2 DNA to determine the number
of copies of viral RNA present in the cultures.
Alu-PCR assay for viral DNA integration detection
Cells were washed and resuspended in DNA-STAT 60
(Tel-Test) to extract genomic DNA following the proto-
col manufacture provided. Extracted DNA was then
used to run Alu-gag PCR [forward primer: 5′-GCC TCC
CAA AGT GCT GGG ATT ACA G-3′; reverse primer
(HIV gag; nt 1505–1486): 5′-GTT CCT GCT ATG TCA
CTT CC-3′]. PCR conditions were as follows: 95 °C ×
2 min (1 ×), followed by 40 cycles of: 95 °C × 15 s, 50 °C ×
15 s, 72 °C × 3.5 min. After Alu-gag PCR, RU5 quantita-
tive real time PCR was carried out with the following
primers and probe. R forward primer (nt 518–539): 5′-
TTA AGC CTC AAT AAA GCT TGC C-3′, U5 reverse
primer (nt 647–628): 5′-GTT CGG GCG CCA CTG
CTA GA-3′, RU5 probe (nt 584–559): 5′-FAM-CCA
GAG TCA CAC AAC AGA CGG GCA CA-MBG-3′) as
directed. Meanwhile, beta-globin was also detected using
the same DNA as template. Forward primer: 5′- CCC
TTG GAC CCA GAG GTT CT-3′, reverse primer: 5′-
CGA GCA CTT TCT TGC CAT GA-3′, probe: 5′- VIC-
GCG AGC ATC TGT CCA CTC CTG ATG CTG TTA
TGG GCG CTC GC-TARAMA-3′) as directed. PCR con-
ditions were as follows: 50 °C × 2 min (1 ×), 95 °C ×
20 s (1 ×); followed by 60 cycles of: 95 °C × 3 s, 60 °C ×
30 s. A standard curve was prepared using known concen-
trations (i.e., copy numbers) of ACH-2 DNA to determine
the number of copies of viral DNA integrated into the
host genome. The primers were used at 900 nM and the
probe at 250 nM.
Detection of HIV-1 reverse transcriptase activity
Infected CD4+ T cells were suspended lysis buffer
[50 mM Tris (pH 7.4), 500 mM NaCl, 1 % Triton X-100,
2 mM PMSF, 20 % glycerol, 1 mM DTT and protease
inhibitor cocktail (Roche)] and vortexed for 60 s. The
mixture was incubated on ice for 45 min and homog-
enized with a small gauge needle by drawing 3 times.
After homogenizing, the mixture was centrifuged at
14,000 × g for 10 min at 4 °C to collect the super-
natant containing HIV-1 reverse transcriptase. Next,
the supernatant was treated with DNase I (Ambion,
Inc.) to remove contaminating DNA. The activity of
HIV-1 reverse transcriptase was detected by EnzChek®
Reverse Transcriptase Assay Kit (Invitrogen) following
the protocol manufacture provided.
Protein extraction
For whole cell extraction, cells were collected and
washed. For viral protein extraction, HIV-1 particles
were collected, washed, and concentrated by centrifu-
ging at 100,000 × g for 2 h at 4 °C. RIPA Lysis Buffer was
then added to cell or viral pellet and vortexed for 60 s.
The mixture was incubated on ice for 45 min and ho-
mogenized with a small gauge needle by drawing 3
times. After homogenizing, the mixture was centrifuged
at 14,000 × g for 10 min at 4 °C to collect the super-
natant (whole cell proteins or viral proteins).
For membrane protein extraction, cells were washed
with cold PBS and membrane proteins were extracted
with membrane protein extraction kit (BioVision) fol-
lowing the protocol manufacture provided.
Western blot assay
Western blotting was carried out following the previous
protocol [29]. After blocking, the membrane was incu-
bated with the primary antibody [goat anti-human
gp120 (Abcam), goat anti-human gp41 (Abcam), goat
anti-human AAT (Bethyl), mouse anti-human CD4
(Immunotech), mouse anti-human CCR5 (Pharmingem),
mouse anti-human CXCR4 (R&D), or rabbit anti-human
β-actin (Abcam)]. Next, secondary antibody [anti-goat
Zhou et al. BMC Microbiology  (2016) 16:172 Page 3 of 12
IgG-HRP (Chemicon international), anti-mouse IgG-
HRP (Chemicon international), or anti-rabbit IgG-HRP
(Chemicon international)] was used to link to the pri-
mary antibody and then developed using ECL Advance
Western Blotting Detection Kit (GE Healthcare).
Immunoprecipitation assay
Extracted proteins were used to carry out immunopre-
cipitation assay following our previous protocol with a
pre-clearing step [24, 25].
Flow cytometry assay
Antibodies used were: CD4 allophycocyanin (APC),
CXCR4 pacific blue, CCR5 fluorescein isothiocyanate
(FITC) and antibody isotope controls were from BD Bio-
sciences. Upon analysis, cells were washed and incubated
for 20 min at room temperature in PBS containing 2 %
BSA and antibodies or antibody isotope controls. Cells
were then collected and washed twice in ice-cold PBS.
The samples were analyzed on flow cytometer. For
CD4+ T cell infection with HIV-1NL4.3 (HIV-1 Gag-iGFP),
activated CD4+ T cells were infected with GFP-labeled
HIV-1NL4.3 and unbound viruses were then removed by
washing three times. GFP in CD4+ T cells was analyzed
on flow cytometer to determine HIV-1 entry.
Membrane receptor interaction identification
For HIV-1 membrane receptor identification, HIV-1 was
washed and concentrated by centrifuging at 100,000 × g
for 2 h at 4 °C. Next, viral particles were incubated with
AAT and dithiobis (succinimidylpropionate) (DSP,
Thermo Scientific) was added to stabilize the interaction
between AAT and HIV-1 membrane protein. Next, the
reaction was stopped by adding Tris buffer and viral
proteins were then extracted following the whole viral
protein extraction protocol described above. For cell
membrane receptor identification, cells were incubated
with AAT. Excess AAT was washed off and DSP was
added to stabilize the interaction between AAT and cel-
lular membrane protein. The reaction was also stopped
by adding Tris buffer and the membrane proteins were
extracted with membrane protein extraction kit (BioVi-
sion) following the provided protocol described above.
Isolated cell membrane proteins or viral membrane
proteins were incubated with AAT-specific antibody
to precipitate proteins that interacted with AAT. Pre-
cipitated proteins were separated by SDS-PAGE and
specific protein bands were cut and digested with a
sequencing grade modified trypsin (Promega) to iden-
tify the proteins by peptide mass fingerprinting assay
using a high-performance liquid chromatography-mass
spectrometry system (HPLC-MS) following the proto-
col described below.
In-gel digestion for peptide mass fingerprinting assay
The proteins were separated by SDS-PAGE and the
appropriate bands were cut for peptide mass finger-
printing assay following our previous protocol [24].
Digested peptides were analyzed on the HPLC-MS
system (Applied Biosystem API QSTAR pulsar I LC/
MS system or Thermo scientific LTQ XL Orbitrap
LC/MS system). The proteins were identified by
searching the specific mass spectrum in the database
(Mascot).
In-gel filter-aided sample preparation (FASP) for peptide
mass fingerprinting assay
Proteins were separated by SDS-PAGE and the appropri-
ate bands were collected for FASP assay following the
previous protocol [24]. The peptides were also analyzed
on Applied Biosystem API QSTAR pulsar I LC/MS sys-
tem. The proteins were identified by searching the spe-
cific mass spectrum in the Mascot database.
Surface plasmon resonance (SPR) assay
AAT, ΔAAT or C-terminus fragment of AAT binding
with gp41 and gp120 was detected on a BIAcore
3000 biosensor system (Pharmacia Biosensor AB)
using SPR assay. Briefly, a carboxymethylated CM5
sensor chip was activated with 1:1 mixture of
0.4 M N-ethyl-N -(3-dimethylaminopropyl) carbodii-
mide and 0.1 M′ N-hydroxysuccinimide. AAT (0.5 g/L in
10 mM NaOAc, pH5), ΔAAT (0.47 g/L in 10 mM NaOAc,
pH5) or synthesized C-terminus fragment of AAT
(0.05 g/L in 10 mM NaOAc, pH5) were then immobi-
lized on the sensor chip by amine-coupling according
to the manufacturer’s instructions. Unreacted sites
were blocked with 1 M ethanolamine/HCl (pH 8).
Control flow cells (blank) were activated and blocked
in the absence of AAT, ΔAAT or synthesized C-
terminus fragment of AAT. Flow cells were routinely
equilibrated with running buffer (PBS, 0.005 % surfac-
tant P20). Analyst gp41 and gp120 were diluted in
the running buffer and allowed to interact with the
sensor surface by a 250-s injection. Different concen-
trations of gp120 and gp41 were injected, each at the
flow rate of 10 μL/min at 25 °C. Data from duplicate
assays were modeled for binding equilibrium.
Statistical analysis
Every experiment was repeated at least three times
with different donors. Analysis of data was performed
using Student t test. P values of ≤ 0.05 were consid-
ered significant. Unless specifically stated, the error
bars indicate the standard errors of the means (SEM).
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Studies using human cells/tissues
Studies using blood or tissue-derived cells obtained from
humans were reviewed and approved by an appropriate
institutional review committee.
Results
Study shows that the C-proximal fragment of AAT (A.A.:
353–372), VIRIP, inhibits HIV-1 infection [12]. However, it
is still unclear whether and how intact AAT inhibits HIV-1
infection and whether VIRIP is the only functional domain.
It is also unknown whether AAT inhibits HIV-1 infection
by targeting virus entry, viral RNA reverse transcription or
viral DNA integration. To address these issues, activated
primary CD4+ T cells were pretreated with AAT at differ-
ent concentrations and then infected with HIV-1NL4.3 with-
out removing AAT in the conditioned complete medium
containing an endocytosis inhibitor cocktail to get rid of
the possible trans-infection of HIV-1 [28]. After infection,
cells were washed and incubated with AAT again (same
condition as before infection) to detect HIV-1 replication.
The results demonstrated that CD4+ Tcells with AAT pre-
treatment produced much less virus than those without
AAT pretreatment. Meanwhile, both of these cells pro-
duced less virus than lymphocytes without AAT treatment
(Fig. 1). These results suggest that, besides inhibiting HIV-
1 replication in infected host cells, intact AAT might also
interfere with HIV-1 infection of uninfected cells. However,
it is still unclear which step(s) AAT targets to exert its in-
hibitory effect on HIV-1 infection.
To determine the mechanism of AAT's inhibition, we
first investigated whether AAT inhibited HIV-1 infection
by blocking viral DNA integration, which is the closest
step to HIV-1 replication. CD4+ T cells were therefore
incubated in the presence or absence of AAT/ΔAAT/C
and then infected with HIV-1NL4.3 without removing the
reagents. Because 0.5–5 g/L AAT inhibits HIV-1 infec-
tion without affecting the viability of CD4+ T cells and
this concentration is within the range found in the hu-
man body (Fig. 1 and Additional file 2: Figure S2) [15,
24], 0.5 g/L AAT was used in the remainder of the study.
Moreover, 0.5 mg/mL AAT also had no obvious effect
on inducing the precipitation of HIV-1NL4.3 particles
(Additional file 3: Figure S3). Meanwhile, relative equiva-
lent amounts of ΔAAT (0.47 g/L) and C (0.05 g/L) were
also included to detect their effect on viral DNA integra-
tion (Fig. 2). The results demonstrated that CD4+ T cells
with AAT pre-treatment had less integrated viral DNA
Fig. 1 AAT inhibited HIV-1 replication. Activated primary CD4+ T
cells were divided into two aliquots. One aliquot was treated with
AAT (0.5, 1, or 5 g/L) for 1 h and then infected with HIV-1NL4.3 for 2
more hours without removing AAT. After infection, unbound viruses
were removed by washing the T lymphocytes for three times and
cells were then cultured with AAT as before infection. The other aliquot
was directly infected with HIV-1NL4.3 for 2 h and unbound viruses were
then removed by washing three times. Infected T cells were then
treated with the presence or absence of AAT. HIV-1 production was
detected by measuring HIV-1 p24 (in the supernatant) at different time
point in each group
Fig. 2 AAT, C and ΔAAT did not directly target on viral DNA integration.
a CD4+ T cells were pretreated in the presence or absence of AAT/C/
ΔAAT and then infected by HIV-1NL4.3 without removing the reagents.
Next, cells were washed to remove unbound viruses and reagents and
then incubated for 1, 6, 12, 18, 24, or 30 h in the presence or absence of
AAT/C/ΔAAT (the same condition as before infection) to isolate genomic
DNA. Viral DNA integration was detected by Alu-PCR. b CD4+ T
cells were also infected with HIV-1NL4.3 without AAT/C/ΔAAT pretreat-
ment. Next, cells were incubated in the presence or absence of AAT, C,
ΔAAT or HIV-1 integrase inhibitor raltegravir (10−4 g/L). After 0, 5, 11,
17, 23, or 29 h incubation, DNA was extracted from these CD4+ T
cells to detect viral DNA integration. Genomic beta-globin was also
detected as the endogenous control. Ct: control group without
reagent treatment; RAL: raltegravir treatment
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(>60 % decrease; p < 0.01). Meanwhile, C-pretreated
CD4+ T cells also had less integrated viral DNA than
AAT-pretreated CD4+ T cells (>70 % decrease; p <
0.001) (Fig. 2a). If CD4+ T cells were infected with HIV-
1NL4.3 at first and then co-cultured with AAT, C, ΔAAT
or HIV-1 integrase inhibitor raltegravir, the results
showed that AAT, C and ΔAAT had no obvious effect
on viral DNA integration while positive control raltegra-
vir almost completely blocked viral DNA integration
without altering the cell viability (>98 % decrease; p <
0.001) (Fig. 2b and Additional file 2: Figure S2). Add-
itionally, the effect of AAT, C and ΔAAT on viral
DNA integration was also tested on different tropism
of primary HIV-1 isolates, HIV-192US714 and HIV-
191US054. The results demonstrated that AAT, C and
ΔAAT also had similar effect on these HIV-1 isolates
(Additional file 4: Figure S4). Thus, these results sug-
gested that AAT and C, not ΔAAT, could inhibit
HIV-1 infection of CD4+ T cells. However, the inhib-
ition was not mediated though directly blocking viral
DNA integration.
Next, we sought to clarify whether AAT blocked HIV-
1 infection by directly interfering with viral RNA reverse
transcription. CD4+ T cells were therefore treated with
AAT/C/ΔAAT and then infected by HIV-1NL4.3 without
removing the reagents. The activity of HIV reverse tran-
scriptase was then measured in CD4+ T cell lysates
(Fig. 3). The results showed that the activity of HIV-1 re-
verse transcriptase in AAT-pretreated CD4+ T cells was
lower than that in untreated CD4+ T cells (>50 % de-
crease; p < 0.05), which could be caused by the lower
amount of HIV-1 reverse transcriptase entry into the
host cells (Fig. 3a). Meanwhile, the activity of HIV re-
verse transcriptase from C-pretreated CD4+ T cells
was also lower than that from AAT-pretreated CD4+
T cells (>50 % decrease; p < 0.005) (Fig. 3a). When
CD4+ T cells were infected first and then cultured
with AAT, C, ΔAAT or HIV-1 reverse transcriptase
inhibitor emtricitabine, the results demonstrated that
AAT, C and ΔAAT had no obvious effect on the ac-
tivity of reverse transcriptase, which confirmed that
the lower activity of HIV-1 reverse transcriptase in
AAT-pretreated CD4+ T cells was due to the lower
amount of HIV-1 reverse transcriptase entry into
these cells (Fig. 3b). As the positive control, emtricita-
bine almost completely blocked the activity of HIV-1
reverse transcriptase without altering the viability of
CD4+ T cells (>98 % decrease; p < 0.001) (Fig. 3b and
Additional file 2: Figure S2). When activated CD4+ T
cells were infected with HIV-192US714 or HIV-191US054,
similar results were also obtained (Additional file 5:
Figure S5). Thus, these results suggested that AAT
inhibited HIV-1 infection by lowering the amount of
virus entry into CD4+ T cells.
To confirm that AAT did inhibit HIV-1 entry, HIV-
1NL4.3 with a GFP insertion within the gag region
(HIV-1 Gag-iGFP) was used to carry out the assay
[30]. As the control for gp120/gp41 and CD4/co-re-
ceptor interaction, HIV-1NL4.3 with a GFP insertion
within the gag region and VSV-G replacing of Env
(VSV-G-pseudotyped HIV-1 Gag-iGFP) was also in-
cluded. Since HIV-1 fusion with host cell leads to
viral core release into the host cell [18], host cells
would obtain GFP signal upon HIV-1 Gag-iGFP infec-
tion. Meanwhile, host cells could not obtain any GFP
signal from VSV-G-pseudotyped HIV-1 Gag-iGFP be-
cause VSV-G-pseudotyped HIV-1 Gag-iGFP did not
Fig. 3 AAT, C and ΔAAT did not directly target viral RNA reverse
transcription. a CD4+ T cells were pretreated with or without AAT/C/
ΔAAT and then infected by HIV-1NL4.3 without removing the
reagents. Infected CD4+ T cells were then washed to remove
unbound viruses and reagents and then incubated for 1, 6, 12,
18, 24, or 30 h in the presence or absence of AAT/C/ΔAAT (the
same condition as before infection) to isolate whole cell proteins
with viral proteins. The activity of HIV-1 reverse transcriptase in normal-
ized whole extracts was detected following the protocol de-
scribed in the Materials and Method. b CD4+ T cells were also
infected with HIV-1NL4.3 without pretreatment and then incubated with
the presence or absence of AAT, C, ΔAAT or HIV-1 reverse
transcriptase inhibitor emtricitabine (10−3 g/L). After 0, 5, 11, 17,
23, or 29 h’ incubation, the whole cell proteins with viral proteins were
extracted from these CD4+ T cells and normalized to detect the
activity of HIV-1 reverse transcriptase. Ct: control group without
reagent treatment; FTC: emtricitabine treatment
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have gp120/gp41 to interact with host cells and the trans-
infection of HIV was blocked with the presence of endo-
cytosis inhibitor cocktails in the conditioned culture
medium. CD4+ T cells were therefore incubated in the
presence or absence of AAT, C, ΔAAT or HIV-1 fusion in-
hibitor enfuvirtide and then cultured with HIV-1NL4.3
Gag-iGFP or VSV-G-pseudotyped HIV-1 Gag-iGFP. After
infection, resultant cells were collected to detect HIV-1
entry on flow cytometer (the gate information was showed
in Additional file 6: Figure S6). As expected, the results re-
vealed that GFP signal was detected only in CD4+ T cells
with HIV-1NL4.3 Gag-iGFP treatment, not VSV-G-
pseudotyped HIV-1 Gag-iGFP. AAT significantly inhibited
HIV-1 entry (>60 % decrease; p < 0.005) (Fig. 4a and b).
The inhibitory effect of C on HIV-1 entry was stronger
than that of AAT (>50 % decrease; p < 0.01) (Fig. 4a and
b). Meanwhile, as the positive control of HIV-1 entry,
enfuvirtide almost completely blocked HIV-1 Gag-iGFP
entry without affecting the viability of these T cells (>90 %
decrease; p < 0.005) (Fig. 4a, b and Additional file 2: Figure
S2). Additionally, cytosolic viral p24 was detected in CD4
+ T cells with HIV-1NL4.3 Gag-iGFP treatment, but not in
CD4+ T cells with VSV-G-pseudotyped HIV-1 Gag-iGFP
treatment. The amount of cytosolic viral p24 was also
lower in AAT-pretreated CD4+ T cells (>60 % decrease;
p < 0.005) (Fig. 4c). The inhibitory effect of C on HIV-
1NL4.3 Gag-iGFP entry was also stronger than that of in-
tact AAT (>50 % decrease; p < 0.01) (Fig. 4c). Meanwhile,
Enfuvirtide treatment completely blocked HIV-1 Gag-
iGFP entry into CD4+ T cells (>90 % decrease; p < 0.001)
(Fig. 4c). Additionally, AAT also inhibited the entry of pri-
mary isolate HIV-192US714 and HIV-191US054 into CD4+ T
cells (Additional file 7: Figure S7). Collectively, these re-
sults confirmed that AAT inhibited HIV-1 infection by
blocking virus entry into CD4+ T cells.
To inhibit HIV-1 entry, AAT could down-regulate CD4,
CXCR4 or CCR5 expression on host T lymphocytes.
However, after CD4+ T cells were treated with AAT, C or
ΔAAT, the expression of these receptors and co-receptors
had no obvious change in the whole cell extract (Fig. 5a).
Meanwhile, AAT, C and ΔAAT also had no obvious effect
on the expression of these receptors on the plasma mem-
brane (Fig. 5b-d) (the gate information for CD4+ T cells
was shown in Additional file 6: Figure S6).
As an alternative mechanism, AAT might directly
interact with CD4, CCR5 or CXCR4, or other known
HIV-1 infection-related proteins on CD4+ T cells to
interfere with the interaction between HIV-1 particles
and host cells. To test this postulate, CD4+ T cells were
incubated with AAT or ΔAAT to precipitate the cyto-
plasm membrane proteins interacting with AAT or
ΔAAT for protein identification by peptide mass finger-
printing assay. The results revealed that precipitated com-
plexes contained low density lipoprotein receptor-related
protein 1, ATP-binding cassette protein and solute carrier
protein, which are not related to HIV-1 entry in CD4+ T
cells [24]. Meanwhile, CD4, CCR5, CXCR4 and other
known HIV-1 infection-related proteins were not detected
in precipitated complexes (data not shown).
As another way to block HIV-1 entry, AAT might dir-
ectly interact with HIV-1 to block its entry into CD4+ T
cells. To test this hypothesis, HIV-1NL4.3 was incubated
with AAT or ΔAAT. Viral membrane proteins interact-
ing with AAT or ΔAAT were then precipitated and iden-
tified by a peptide mass fingerprinting assay. The results
revealed that precipitated complexes from the AAT/
HIV-1NL4.3 co-culture system contained gp120 and gp41.
However, no viral protein was detected in the precipitated
Fig. 4 AAT and C inhibited HIV-1 entry in CD4+ T cells. CD4+ T cells
were pretreated in the presence or absence of AAT, C, ΔAAT or
HIV-1 entry inhibitor enfuvirtide (10−3 g/L) and then infected by
HIV-1NL4.3 (HIV-1 Gag-iGFP) or VSV-G-pseudotyped HIV-1 NL4.3
(VSV-G-pseudotyped HIV-1 Gag-iGFP) without removing the reagents.
Next, infected CD4+ T cells were collected to detect GFP on flow
cytometer. As the negative control, one group of non-infected CD4+ T
cells was also analyzed (Non-infec Ct) (a). The mean fluorescence
intensity of each group was also plotted from three in-dependent
experiments on three different donors (b). Meanwhile, these CD4+ T
cells were also collected to extract whole cell proteins. HIV-1 entry into
CD4+ T cells were determined by measuring cytosolic HIV-1 p24 (c). Ct:
HIV-1 Gag-iGFP-infected CD4+ T cells without reagent treatment.
Pseudo: VSV-G-pseudotyped HIV-1 Gag-iGFP-treated CD4+ T cells
without reagent treatment; ENF: enfuvirtide treatment; Non-infec Ct:
non-infected CD4+ T cells
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complexes from the ΔAAT/HIV-1NL4.3 co-culture sys-
tem (Fig. 6a). Moreover, gp120 and gp41 were also de-
tected in precipitated viral proteins from AAT/HIV-
1NL4.3 by Western blot. However, gp120 and gp41 could
not be detected in precipitated viral membrane proteins
from ΔAAT/HIV-1NL4.3 (Fig. 6b). Furthermore, when
HIV-1NL4.3 was co-cultured with AAT or ΔAAT to pre-
cipitate virus with gp120 antibody, only AAT was found
to directly interact with HIV-1 (Fig. 6c). When AAT, C
or ΔAAT was co-cultured with gp120 or gp41 to detect
the interaction between AAT/C/ΔAAT and gp120/gp41,
the results demonstrated that C and AAT could directly
interact with gp41 (Fig. 6d). When AAT, C or ΔAAT
was immobilized on a carboxymethylated CM5 sensor
chip and gp120 or gp41 was then applied to detect the
direct interaction by SPR assay, the results revealed that
only gp41 interacted with AAT and C (Fig. 7). There-
fore, these results together suggested that the C-
terminus of AAT, but not other domains, directly inter-
acted with gp41, which might mediate the inhibition of
HIV-1 entry.
Discussion
The study of a clinic case reveals that pre-existing AAT
deficiency is associated with accelerated HIV/AIDS pro-
gression [13, 18]. Studies reveal that AAT inhibits HIV-
1 replication [10, 11, 14, 15]. Constitutive expression
of AAT inhibits HIV-1 replication by blocking gp160
and p55 processing in cell lines or primary human
lymphocytes [31]. Meanwhile, AAT also inhibits HIV-
1 replication by blocking the activation of NF-kB [14,
15, 24, 25, 32]. In the present study, we found that
viral replication in AAT-pretreated CD4+ T cells was
much lower than that in CD4+ T cells without AAT
pretreatment, suggesting that AAT might exert its in-
hibitory effect on both HIV-1 infection and replica-
tion. However, several critical issues still need to be
addressed. In the present study, our results show that
AAT and C, but not ΔAAT, directly interact with
gp41, which might then inhibit HIV-1 entry into CD4
+ T cells. Moreover, AAT/ΔAAT/C did not directly
interfere with the steps of viral RNA reverse tran-
scription and viral DNA integration. To our surprise,
the activity of HIV-1 reverse transcriptase decreased
with the elongation of incubation time of the cells.
This might be caused by the degradation of HIV-1 re-
verse transcriptase in the cytosol of CD4+ T cells,
which is a general bioprocess in the cell and also
leaves us a good topic to follow in the future. There-
fore, these observations eliminate the concerns that
52KD AAT might be too big to directly interact with
gp120-covered gp41 on the membrane of HIV-1 viral
Fig. 5 AAT, C and ΔAAT had no obvious effect on CD4, CCR5 and CXCR4 expression on CD4+ T cells. CD4+ T cells were incubated in the
presence or absence of AAT/C/ΔAAT and then collected to extract whole cell proteins. The expression of CD4, CCR5 and CXCR4 was detected by
Western blot. β-actin was detected as the loading control (a). Meanwhile, the membrane level of CD4 (b), CCR5 (c) and CXCR4 (d) was
also analyzed on these CD4+ T cells using flow cytometry. Ct: control group without reagent treatment
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particle. The results also indicate that AAT C-
terminus is the only essential functional domain to
inhibit HIV-1 infection.
Normally, HIV-1 infection begins with the interaction
between gp120/gp41 and CD4/co-receptors, which is
then followed by viral core entry, RNA reverse transcrip-
tion and DNA integration into the host genome [19, 22].
In the present study, AAT, C and ΔAAT did not directly
target the steps of viral RNA transcription and viral
DNA integration, which means that AAT inhibits HIV-1
infection through blocking virus entry. Although studies
demonstrate that AAT inhibits HIV-1 replication in in-
fected lymphocytes [10–15, 31], relatively fewer reports
investigate whether AAT inhibits HIV-1 infection of
Fig. 6 AAT and C directly interacted with gp41. HIV-1NL4.3 was incubated in the presence or absence of AAT/ΔAAT and then concentrated by
ultracentrifugation (100,000 × g for 2 h at 4 °C) to extract viral proteins. AAT antibody was then added to viral proteins to precipitate proteins
interacting with AAT/ΔAAT. Next, each specific protein was identified by peptide mass fingerprinting assay (a). Meanwhile, after concentrating,
the virus was also divided into two aliquots. One aliquot was lysed to extract whole viral proteins and AAT antibody was then added to precipitate
the proteins interacting with AAT/ΔAAT. AAT, gp120 or gp41 in the precipitated proteins were detected by immunoblotting (b). The other aliquot was
incubated with gp120 antibody to precipitate proteins interacting with viral particles. Subsequently, precipitated viruses were lysed to detect AAT,
gp120 and gp41 by Immunoblotting (c). Moreover, AAT/C/ΔAAT was also cultured with gp120 or gp41. Next, gp120 or gp41 antibody was added to
precipitate. The direct interaction between AAT/C/ΔAAT and gp120/gp41 was determined by separating precipitated proteins with SDS-PAGE and
proteins were visualized by Coomassie blue staining (d). MW: molecular weight marker; IP: immunoprecipitation; WB: western blotting (immunoblotting)
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uninfected cells and the mechanism is not fully eluci-
dated yet. Usually, HIV-1 entry into host cells involves
the interaction between viral gp120/gp41 and host CD4/
CXCR4 or CCR5 [33]. Some researchers, however, sug-
gest that AAT inhibition of HV-1 entry is related to the
interaction between AAT and host cell membrane pro-
teins [34]. In the present study, our results did not pro-
vide any indication to suggest that AAT interacts with
host membrane proteins, thereby inhibiting HIV-1 entry.
AAT also did not alter the expression of CD4, CXCR4
and CCR5. Moreover, AAT also did not directly interact
with CD4, CCR5, CXCR4 and other HIV-1 infection-
related proteins. In contrast, AAT directly interacted
with viral gp41. These observations together suggest that
intact AAT could interact with viral gp41 to interfere
with the interaction between gp120/gp41 and CD4/
CCR5 or/CXCR4 and thereby inhibiting HIV-1 entry,
which is consistent with previous studies [35]. Moreover,
AAT without the C-terminus could not interact with
gp41, which indicates that the C-terminus of AAT is an
essential functional domain. Munch et al.’s study also re-
veals that VIRIP at the C-terminus of AAT inhibits HIV-
1 infection [12]. When ΔAAT, AAT or synthesized C-
terminus fragment of AAT was cultured with gp41 or
gp120, we detected direct interaction between AAT/syn-
thesized C-terminus fragment of AAT, but not ΔAAT,
and gp41. Thus, collectively with the findings of Munch’s
[13], it is clear that the inhibitory effect of AAT on HIV-
1 infection is mediated through the direct interaction
between the C-terminus of AAT and gp41, which then
interferes with the entry of HIV-1 into the host cells.
Conclusion
Studies have showed that AAT inhibits HIV-1 replica-
tion [15, 36]. Our previous study reveals that AAT en-
ters the cytosol of infected CD4+ T cells and directly
interacts with cytosolic IkBα to alter its ubiquitinylation
pattern. The change of IkBα ubiquitinylation pattern
Fig. 7 SPR assay of AAT/C and gp41 interaction. gp120 (6.25–200 μg/mL) and gp41 (18.75–600 μg/mL) were analyzed for binding to immobilized
AAT, C or ΔAAT. Representative Sensorgrams were displayed and the amount of bound gp120 or gp41 was shown over time. Binding curves revealing
saturable kinetics for the interaction were also plotted
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results in the inhibition of NF-kB activation [15, 24].
In infected cells, NF-kB activation is critical for HIV-1
replication [37]. In the present study, our results reveal
that AAT inhibits HIV-1 infection not by directly targeting
the steps of viral RNA reverse transcription and viral
DNA integration. The inhibitory effect of AAT on HIV-1
infection is mediated through the direct interaction be-
tween AAT's C-terminus and gp41, which thereby inhibits
HIV-1 entry into the host cells. Therefore, these results to-
gether indicate that AAT works through multiple ways to
exert its inhibitory effects on HIV/AIDS pathogenesis,
which may provide useful information for drug develop-
ment for HIV/AIDS treatment.
Additional files
Additional file 1: Figure S1. Purity and quality of AAT, ΔAAT and C.
ΔAAT was prepared following the protocol in Materials and. Next, AAT,
purified ΔAAT and C were analyzed on 4–20 % Tris-Glycin SDS-PAGE gel
and analyzed by in-gel digestion mass fingerprinting assay (A). Aligned
sequences were also shown for AAT, ΔAAT and C (B). (TIF 6959 kb)
Additional file 2: Figure S2. AAT, raltegravir, emtricitabine and
enfuvirtide had no obvious effect on the viability of CD4+ T cells. CD4+ T
cells were pretreated with or without AAT for 1 h. Next, these cells were
incubated with AAT, raltegravir (10−4 g/L), emtricitabine (10−3 g/L), or
enfuvirtide (10−3 g/L) for indicated time period. At the end of incubation,
cells were collected to detect the viability using trypan blue staining.
RAL: raltegravir treatment; FTC: emtricitabine treatment; ENF: enfuvirtide
treatment. (TIF 975 kb)
Additional file 3: Figure S3. 0.5 mg/mL AAT did not induce the
precipitation of HIV-1NL4.3 particles. Same amount of HIV-1NL4.3 viral
stock was incubated with the presence or absence of 0.5 mg/mL AAT
(final concentration) and activated CD8+ T cells (10 million in 1 mL; the
same concentration as CD4+ T cells to work as a cell loading control).
The final concentration and volume for HIV-1NL4.3, AAT and CD8+ T cells
were adjusted to be the same as CD4+ T cells infection system. After 2 h’
incubation with gentle shaking at 37° (same as CD4+ T cells infection
procedure), the mixtures were centrifuged for 15 min at 10,000 × g to
pellet down any possible precipitation. The supernatant was collected to
detect HIV-1 p24 (A) and viral RNA (B). (TIF 1557 kb)
Additional file 4: Figure S4. AAT, C and ΔAAT did not directly target
the integration of primary HIV-1 DNA into the host genome. CD4+ T
were incubated in the presence or absence of AAT/C/ΔAAT and then
infected by HIV-191US054 (A) or HIV-192US714 (C) without removing reagents.
Next, infected CD4+ T cells were washed to remove unbound viruses
and reagents and incubated for 1, 6, 12, 18, 24, or 30 h in the presence
or absence of AAT/C/ΔAAT (same condition as before infection) to isolate
DNA. The integration of HIV-1 viral DNA was detected by Alu-PCR (A and
C). Additionally, CD4+ T cells were also infected with HIV-191US054 (B) or
HIV-192US714 (D) without AAT/C/ΔAAT pretreatment and then incubated
with the presence or absence of AAT/C/ΔAAT. After 0, 5, 11, 17, 23, or
29 h’ incubation, DNA was extracted to detect viral DNA integration (B
and D). Genomic beta-globin was also detected as an endogenous
control. (TIF 1195 kb)
Additional file 5: Figure S5. AAT, C and ΔAAT did not directly affect
the activity of HIV-1 reverse transcriptase. CD4+ T cells were pretreated in
the presence or absence of AAT/C/ΔAAT and then infected by HIV-191US054
(A) or HIV-192US714 (C) without removing the reagents. Infected CD4+ T cells
were then washed three times to remove unbound viruses and incubated
in the presence or absence of AAT/C/ΔAAT (same condition as before
infection) for 1, 6, 12, 18, 24, or 30 h to isolate whole cell and viral proteins.
HIV-1 reverse transcriptase activity was detected. Meanwhile, CD4+ T cells
were also infected with primary HIV-191US054 (B) or HIV-192US714 (D) without
AAT/C/ΔAAT pretreatment and then incubated in the presence or absence
of AAT/C/ΔAAT. After 0, 5, 11, 17, 23, or 29 h incubation, whole cell proteins
with viral proteins were extracted from these CD4+ T cells to detect the
activity of HIV-1 reverse transcriptase. (TIF 1480 kb)
Additional file 6: Figure S6. Flow cytometry gate information for CD4
+ T cell selection and CD4/CCR5/CXCR4 detection on selected CD4+ T
cells. (TIF 8012 kb)
Additional file 7: Figure S7. AAT and C inhibited HIV-1 entry. CD4+ T
cells were treated in the presence or absence of AAT/C/ΔAAT and then
infected by HIV-191US054 (A) or HIV-192US714 (B) without removing the
reagents. Next, infected CD4+ T cells were collected to extract whole
cell proteins (including p24). HIV-1 entry was determined by measuring
cytosolic p24. (TIF 327 kb)
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